UBS Group’s Sophiris Bio, Inc. SPHS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-11,426
| Closed | -$4K | – | 8927 |
|
|
2019
Q4 | $4K | Buy |
11,426
+5,914
| +107% | +$2.69K | ﹤0.01% | 7719 |
|
|
2019
Q3 | $3K | Sell |
5,512
-1,560
| -22% | -$1.39K | ﹤0.01% | 7710 |
|
|
2019
Q2 | $6K | Buy |
7,072
+198
| +3% | +$173 | ﹤0.01% | 7356 |
|
|
2019
Q1 | $6K | Sell |
6,874
-9,127
| -57% | -$9.8K | ﹤0.01% | 7136 |
|
|
2018
Q4 | $14K | Buy |
16,001
+10,489
| +190% | +$20.6K | ﹤0.01% | 7080 |
|
|
2018
Q3 | $15K | Hold |
5,512
| – | – | ﹤0.01% | 6990 |
|
|
2018
Q2 | $15K | Hold |
5,512
| – | – | ﹤0.01% | 6923 |
|
|
2018
Q1 | $11K | Hold |
5,512
| – | – | ﹤0.01% | 6841 |
|
|
2017
Q4 | $13K | Hold |
5,512
| – | – | ﹤0.01% | 6901 |
|
|
2017
Q3 | $12K | Sell |
5,512
-488
| -8% | -$1.01K | ﹤0.01% | 6814 |
|
|
2017
Q2 | $13K | Sell |
6,000
-3,228
| -35% | -$7.91K | ﹤0.01% | 6630 |
|
|
2017
Q1 | $26K | Sell |
9,228
-118
| -1% | -$323 | ﹤0.01% | 5973 |
|
|
2016
Q4 | $26K | Buy |
9,346
+5,346
| +134% | +$15.1K | ﹤0.01% | 6366 |
|
|
2016
Q3 | $12K | Buy |
+4,000
| New | +$15K | ﹤0.01% | 6700 |
|
|
2016
Q1 | – | Sell |
-12,830
| Closed | -$23K | – | 8867 |
|
|
2015
Q4 | $23K | Buy |
+12,830
| New | +$19K | ﹤0.01% | 6634 |
|
|
2015
Q2 | – | Sell |
-4,851
| Closed | -$3K | – | 9343 |
|
|
2015
Q1 | $3K | Sell |
4,851
-4,089
| -46% | -$2.19K | ﹤0.01% | 8407 |
|
|
2014
Q4 | $5K | Buy |
+8,940
| New | +$20.7K | ﹤0.01% | 9076 |
|
Other funds holding SPHS
UBS Group's SPHS Position: Q1 2020 in Review
UBS Group sold out of Sophiris Bio, Inc. (SPHS) in Q1 2020, closing a stake of 11,426 shares — an estimated $4K sold.
UBS Group first reported a position in SPHS in Q4 2014 and held it in 17 quarters. The position peaked at $26K in Q1 2017. 3 funds tracked by Wall St. Rank hold SPHS as of Q1 2020.
- UBS Group reported no remaining Sophiris Bio, Inc. position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 11,426 Sophiris Bio, Inc. shares in Q1 2020, an estimated $4K.
- UBS Group first reported a position in Sophiris Bio, Inc. in Q4 2014 and held it in 17 quarters.
- UBS Group's Sophiris Bio, Inc. position peaked at $26K in Q1 2017.
- 3 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.